iiinova — where your digital self keeps evolving

Ihsane Hmamouchi @epirheum.bsky.social · 12/07/2026

📄 Le NEJM vient de rétracter ADVOCATE, l'essai pivot de l'avacopan (Tavneos) dans la vascularite à ANCA. Une 1ère en 200 ans d'existence de la revue : jamais un essai ayant servi de base à une autorisation réglementaire n'avait été rétracté. On décrypte epirheum.com/1623-2/

epirheum.com

Zoom sur la rétractation de l’étude ADVOCATE par le NEJM: quand la réadjudication post-hoc trahit l’aveugle

Le 29 juin dernier, le New England Journal of Medicine a rétracté l'étude ADVOCATE. ADVOCATE est l'essai pivot ayant permis

100

Ihsane Hmamouchi @epirheum.bsky.social · 06/06/2026

Proud to join the new Lancet Rheumatology Commission on reproductive health & family planning in RMDs 👏🏽 Kicked off on June 2nd in London. Multidisciplinary. Patient-centred. Policy-focused. Report in 4–5 years. Looking forward to seeing where this work takes us 🌟 #EULAR2026 #RMDs #ReproductiveHealth

010

Reposted by Ihsane Hmamouchi

Annals of the Rheumatic Diseases @ard.eular.org · 06/06/2026

Excellent overview by Raj Sengupta on early treatment in early #axSpA. ▶️The accumulating evidence supports the importance of early diagnosis, early target attainment, and intervention during the window of opportunity to optimize long-term outcomes. #EULAR2026

021

Reposted by Ihsane Hmamouchi

Annals of the Rheumatic Diseases @ard.eular.org · 05/06/2026

Kicking off Day 3 of #EULAR2026 with an WIN plenary session on pregnancy and fertility management in patients living with RMDs. Looking forward to the discussions and latest insights!

041

Reposted by Ihsane Hmamouchi

ero.eular.org @ero.eular.org · 04/06/2026

📊 New data from the SPACE cohort evaluates the 2025 ASAS-SPARTAN #axSpA criteria! The revised sets prioritise specificity (💥 all >94% regardless of reader). 📉 However, massive drop-off in sensitivity. For local readers, 83.0% (2009 criteria) down to just 60.2%. #EULAR2026 #OP0239

155

Ihsane Hmamouchi @epirheum.bsky.social · 04/06/2026

Learning from Setbacks: The hidden value of unsuccessful Trials A thought-provoking discussion at #EULAR2026 on why every well-conducted trial moves science forward.

031

Reposted by Ihsane Hmamouchi

Annals of the Rheumatic Diseases @ard.eular.org · 04/06/2026

Direct from #EULAR2026 ▶️Perimenopause is associated with increased disease activity in PsA ▶️Rheumatologists should be aware of possible flares of PSA during peri-menopause ➡️ Research is needed to understand the effect of sex-effect in different life stages of PsA

052

Reposted by Ihsane Hmamouchi

ero.eular.org @ero.eular.org · 04/06/2026

Influence of menopause status on disease activity and remission in RA: BIOPURE study #EULAR2026

043

Reposted by Ihsane Hmamouchi

ero.eular.org @ero.eular.org · 04/06/2026

Hope is still blowing in #SjögrensDisease at #EULAR26! OP0160 TYK2 inhibition signature is shared in #SLE and #SjD 🔬 TYK2 inhibition signature is associated with disease activity 🔥 Let's wait for the results of the phase 3 trials of TYK inhibition in both diseases ⏳

031

Reposted by Ihsane Hmamouchi

ero.eular.org @ero.eular.org · 04/06/2026

043

Reposted by Ihsane Hmamouchi

The Journal of Rheumatology @jrheumatol.bsky.social · 24/11/2025

Panorama Engaging Arabic-Speaking Patients With Rheumatic Diseases Through Social Media: A Multinational Infodemiology Analysis 📖 doi.org/10.3899/jrhe... @epirheum.bsky.social @rheumcat.bsky.social @nellziade.bsky.social #SocialMedia #Arabic #Rheumatology

032

Ihsane Hmamouchi @epirheum.bsky.social · 05/02/2025

🌍 Wrapped up the #GlobalHealth module with Master students @UIR university of rabat! We explored health #literacy, #digital access, & the U.S. withdrawal from WHO, sparking insightful debates & fresh perspectives. 👏 Well done to all & looking forward where your ideas take you next!

020

Reposted by Ihsane Hmamouchi

Rheum Cat @rheumcat.bsky.social · 01/02/2025

🚨 The CDC just pulled all BRFSS data & documentation offline, along with other datasets. This is a huge loss for public health research. What does it mean? Why does it matter? Here's what I learned from using BRFSS for one of my first studies: pubmed.ncbi.nlm.nih.gov/32541614/

33812

Ihsane Hmamouchi @epirheum.bsky.social · 10/12/2024

📢 Honored to share at #SFR24 our study on a tailored benchmark index for Arabic-language rheumatology awareness campaigns. 🗣️An approach addressing dialectal diversity and working with low-resource data to drive impactful insights. A big thank you to our incredible team 🤩 #ArabicDataInsights

000

Ihsane Hmamouchi @epirheum.bsky.social · 24/11/2024

New NEJM article explores Target Trial Emulation—a method to align observational studies with RCT principles. While promising for reducing bias, it depends on robust data and careful design. A powerful tool, but no substitute for RCTs. www.nejm.org/doi/full/10.... #Epidemiology #Biostatistics

nejm.org

“Target Trial Emulation” for Observational Studies — Potential and Pitfalls | NEJM

To improve the quality of observational studies, target trial emulation requires careful specification of design elements, analytic methods for addressing confounding, and reporting of sensitivity ...

012

Ihsane Hmamouchi @epirheum.bsky.social · 23/11/2024

That’s a wrap! From Marrakech 🇲🇦 to Belo Horizonte 🇧🇷 At the 20th #ICUH in Marrakech, UIR-IPORA One Health panel 😊 Insights ranged from salutogenic landscapes to global-local approaches for healthier cities. fostering collaboration to build resilient urban futures!! #OneHealth #UrbanHealth

000